High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial

S Vliek, FS Hilbers, E van Werkhoven, I Mandjes, R Kessels, S Kleiterp, EH Lips, L Mulder, MT Kayembe, CE Loo, NS Russell, MJTFDV Peeters, MJ Holtkamp, M Schot, JW Baars, AH Honkoop, AJE Vulink, ALT Imholz, S Vrijaldenhoven, FWPJ van den BerkmortelJMM Terwogt, JG Schrama, P Kuijer, JR Kroep, A van der Padt-pruijsten, J Wesseling, GS Sonke, KGA Gilhuijs, A Jager, P Nederlof, SC Linn

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
6 Downloads (Pure)

Fingerprint

Dive into the research topics of 'High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Agricultural and Biological Sciences

Immunology and Microbiology